| Autor: |
Aitken JF; School of Biological Sciences, University of Auckland, New Zealand., Loomes KM; School of Biological Sciences, University of Auckland, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, New Zealand., Riba-Garcia I; Centre for Advanced Discovery and Experimental Therapeutics, CMFT, Manchester Academic Health Sciences Centre, and Institute of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, UK., Unwin RD; Centre for Advanced Discovery and Experimental Therapeutics, CMFT, Manchester Academic Health Sciences Centre, and Institute of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, UK., Prijic G; School of Biological Sciences, University of Auckland, New Zealand., Phillips AS; Michael Barber Centre for Collaborative Mass Spectrometry, Manchester Institute of Biotechnology, University of Manchester, UK., Phillips AR; School of Biological Sciences, University of Auckland, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, New Zealand; Department of Surgery, Faculty of Medical & Health Sciences, University of Auckland, New Zealand., Wu D; Key Laboratory of Regenerative Biology and Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China; Joint School of Biological Sciences, Guangzhou Institute of Biomedicine and Health, Guangzhou Medical University, Guangzhou, China., Poppitt SD; School of Biological Sciences, University of Auckland, New Zealand., Ding K; College of Pharmacy, Jinan University, Guangzhou, China., Barran PE; Michael Barber Centre for Collaborative Mass Spectrometry, Manchester Institute of Biotechnology, University of Manchester, UK., Dowsey AW; Centre for Advanced Discovery and Experimental Therapeutics, CMFT, Manchester Academic Health Sciences Centre, and Institute of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, UK; School of Social & Community Medicine, Faculty of Health Sciences, University of Bristol, UK., Cooper GJ; School of Biological Sciences, University of Auckland, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, New Zealand; Centre for Advanced Discovery and Experimental Therapeutics, CMFT, Manchester Academic Health Sciences Centre, and Institute of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, UK. |
| Abstrakt: |
Here we provide data describing the time-course of blood-glucose and fluid-intake profiles of diabetic hemizygous human-amylin (hA) transgenic mice orally treated with rutin, and matched control mice treated with water. We employed "parametric change-point regression analysis" for investigation of differences in time-course profiles between the control and rutin-treatment groups to extract, for each animal, baseline levels of blood glucose and fluid-intake, the change-point time at which blood glucose (diabetes-onset) and fluid-intake (polydipsia-onset) accelerated away from baseline, and the rate of this acceleration. The parametric change-point regression approach applied here allowed a much more accurate determination of the exact time of onset of diabetes than do the standard diagnostic criteria. These data are related to the article entitled "Rutin suppresses human-amylin/hIAPP misfolding and oligomer formation in-vitro , and ameliorates diabetes and its impacts in human-amylin/hIAPP transgenic mice" (J.F. Aitken, K.M. Loomes, I. Riba-Garcia, R.D. Unwin, G. Prijic, A.S. Phillips, A.R.J. Phillips, D. Wu, S.D. Poppitt, K. Ding, P.E. Barran, A.W. Dowsey, G.J.S. Cooper. 2016) [1]. |
